サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1701234

コンパニオン診断市場規模、シェア、動向分析レポート：製品・サービス別、適応症別、技術別、製品タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年

Companion Diagnostics Market Size, Share & Trends Analysis Report By Product And Services, By Indication, By Technology, By Sample Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
コンパニオン診断市場規模、シェア、動向分析レポート：製品・サービス別、適応症別、技術別、製品タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年03月11日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コンパニオン診断市場の成長と動向

Grand View Research, Inc.の最新レポートによると、コンパニオン診断の世界市場規模は、2025～2030年にかけて10.5%のCAGRを記録し、2030年までに159億8,000万米ドルに達する見込みです。

コンパニオン診断は、患者の対応するバイオマーカーを特定することにより、特定の治療の安全かつ効果的な使用を保証するために設計された特殊な検査です。これらの検査は主に腫瘍学で採用されており、患者固有の遺伝子プロファイルに基づいて最も適切な標的療法を選択する際に臨床医を導きます。例えば、ファウンデーション・メディシンのFOUNDATIONONE CDxは、300以上のがん関連遺伝子を分析し、様々な固形がんにおける精密がん治療に役立つ重要な洞察を記載しています。コンパニオン診断は、重要な変異や遺伝子変化を同定することで、個別化治療レジメンを促進し、それによって臨床転帰を改善し、副作用のリスクを低減します。このような個別化された治療アプローチは、患者さんの治療を向上させるだけでなく、患者さん一人一人の遺伝子構成に合わせた治療戦略をとるプレシジョン・メディシン（精密医療）への幅広いシフトをサポートします。

コンパニオン診断市場は、特にがん領域において、規制当局の承認が極めて重要な役割を果たしています。2022年8月、米国FDAはThermo Fisher ScientificのOncomine Dx Target Testを承認しました。このコンパニオン診断は、非小細胞肺がん腫瘍のHER2（ERBB2）活性化変異（一塩基変異やエクソン20挿入を含む）を同定するようデザインされています。このような規制当局の承認は、これらの検査の臨床的有用性を検証し、その普及を促進するものです。さらに、次世代シーケンス（NGS）のような先進的技術の使用はコンパニオン診断に不可欠となっています。NGSは臨床医が複数の遺伝子を同時に評価することを可能にし、それによって包括的な腫瘍プロファイリングを記載しています。米国疾病予防管理センター（CDC）は、NGSが過去5年以内に研究ツールから臨床的に承認された方法への移行に成功したことを強調し、診断アプリケーションにおけるその重要性の高まりを強調しています。

技術革新はコンパニオン診断市場の成長の重要な促進要因です。主要な産業参入企業は、診断の精度と効率を向上させるために、NGSプラットフォーム、デジタルELISA、リキッドバイオプシー技術を継続的に進化させています。例えば、2023年11月、QIAGENはElement Biosciencesと提携し、ベンチトップシーケンサーAVITIシステムにNGSワークフローを提供することで、ゲノム研究における探索の強化、コスト削減、納期短縮を目指しています。同様に、2022年1月、IlluminaはSomaLogic Operating Co., Inc.と協業し、SomaScanプロテオミクスアッセイを高スループットNGSプラットフォームに統合しました。これらの提携は、コンパニオン診断の技術的能力を拡大するだけでなく、新たな検査ソリューションの開発におけるイノベーションを促進し、新たな診断法が進化する臨床ニーズに対応することを確実にします。

世界のがん罹患率の増加は、コンパニオン診断の導入に大きく拍車をかけています。ゲノム検査は、効果的な治療プロトコルを選択するために不可欠な腫瘍生物学に関する詳細な知見を提供するからです。米国がん学会誌のデータによると、米国では2022年に約190万人の新規がん症例が報告され、一方、世界保健機関（WHO）は同年、世界中で226万人の新規乳がん症例と221万人の新規肺がん症例が報告されたと指摘しています。こうした課題に対応するため、特定の遺伝子変異を検出する新しい検査法の開発が進められています。例えば、2020年8月、米国FDAは、転移性非小細胞肺がんにおけるEGFR遺伝子変異を検出するNGS技術を採用した初のリキッドバイオプシーコンパニオン診断であるGuardant360 CDxを承認しました。2023年10月、QIAGENはMyriad Geneticsと提携し、がん領域における先進的コンパニオン診断ソリューションを開発することで、個別化治療戦略を強化し、患者の転帰を改善することで、市場での地位をさらに強化しました。

コンパニオン診断市場レポートハイライト

  • 製品とサービス別では、アッセイ、キット、試薬が2024年に59.1%のシェアで市場をリードしています。これらのコンポーネントは、特に腫瘍学、心血管疾患、希少遺伝性疾患において、患者の精密治療の適格性を判断するのに役立つ特定のバイオマーカーを検出する上で極めて重要です。
  • 適応症別では、世界のがん罹患率の増加と個別化医療に対する需要の高まりにより、2024年にはがん領域が圧倒的な市場シェアを占めています。CDxは、標的治療の選択に役立つバイオマーカーの同定に重要な役割を果たし、がん患者の治療成績を改善します。
  • 技術別では、ポリメラーゼ連鎖反応（PCR）セグメントが2024年のコンパニオン診断市場を独占し、27.7%のシェアを占めました。リアルタイムPCR法は、その高い特異性と感度により広く使用されており、がんバイオマーカーの同定に好ましい方法となっています。
  • サンプルのタイプ別では、組織サンプルが2024年に62.7%の最大市場シェアを占め、標的治療のためのバイオマーカーベースの組織検査の広範な採用が牽引しています。組織サンプルは、固形腫瘍の遺伝子変異やタンパク質発現の同定に不可欠であり、腫瘍学の精密医療を導きます。
  • 最終用途別では、病院と医師による検査部門ががんコンパニオン診断市場を独占し、2024年には38.6%のシェアを占めます。病院は通常、増加するがん負担と高齢化に対処するため、包括的ながん診断検査を提供しています。
  • 北米は2024年の市場シェア40.2%で世界市場を独占しました。その主要理由は、先進的な医療インフラ、多額の医療費、新しい診断技術の承認を迅速に行う強固な規制の枠組みです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 コンパニオン診断市場の変数、動向、範囲

  • 市場イントロダクション/系統展望
  • 市場規模と成長展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • コンパニオン診断市場分析ツール
    • ポーター分析
    • PESTEL分析
    • パイプライン
    • 使用事例

第4章 コンパニオン診断市場：製品とサービス別、推定・動向分析

  • セグメントダッシュボード
  • コンパニオン診断市場：製品とサービスの変動分析、2024年と2030年
  • アッセイ、キット、試薬
  • 機器とシステム
  • ソフトウェアとサービス

第5章 コンパニオン診断市場：適応症別、推定・動向分析

  • セグメントダッシュボード
  • コンパニオン診断市場：適応症変動分析、2024年と2030年
  • 腫瘍学
  • 感染症
  • 心血管疾患
  • 神経疾患
  • その他

第6章 コンパニオン診断市場：技術別、推定・動向分析

  • セグメントダッシュボード
  • コンパニオン診断市場：技術変動分析、2024年と2030年
  • ポリメラーゼ連鎖反応（PCR）
  • 次世代シーケンス（NGS）
  • in situーハイブリダイゼーション（ISH）
  • 免疫組織化学（IHC）
  • 磁気共鳴画像法（MRI）
  • その他

第7章 コンパニオン診断市場：サンプルタイプ別、推定・動向分析

  • セグメントダッシュボード
  • コンパニオン診断市場：サンプルタイプ変動分析、2024年と2030年
  • 組織サンプル
  • 血液サンプル
  • その他

第8章 コンパニオン診断市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • コンパニオン診断市場：最終用途変動分析、2024年と2030年
  • 学術研究センター
  • 病院と医師の検査室
  • CRO
  • リファレンスラボ
  • 製薬とバイオテクノロジー企業
  • その他

第9章 コンパニオン診断市場：地域別、推定・動向分析

  • コンパニオン診断市場シェア（地域別、2024年と2030年）
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業ヒートマップ分析
  • 企業プロファイル
    • QIAGEN
    • Agilent Technologies, Inc.
    • Abbott
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann La Roche Ltd
    • Foundation Medicine
    • Myriad Genetics
    • Illumina, Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global companion diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 4 Global companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 5 Global companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Global companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 7 Global companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 North America companion diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 10 North America companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 11 North America companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 12 North America companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 13 North America companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 U.S. companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 15 U.S. companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 16 U.S. companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 17 U.S. companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 18 U.S. companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Canada companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 20 Canada companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Canada companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Canada companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 23 Canada companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Mexico companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 25 Mexico companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Mexico companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Mexico companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 28 Mexico companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Europe companion diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 30 Europe companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 31 Europe companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Europe companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 33 Europe companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 34 Europe companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 UK companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 36 UK companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 37 UK companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 38 UK companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 39 UK companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Germany companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 41 Germany companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Germany companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Germany companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 44 Germany companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 France companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 46 France companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 47 France companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 48 France companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 49 France companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Italy companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 51 Italy companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Italy companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Italy companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 54 Italy companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Spain companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 56 Spain companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 57 Spain companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Spain companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 59 Spain companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Denmark companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 61 Denmark companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Denmark companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 63 Denmark companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 64 Denmark companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Sweden companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 66 Sweden companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 67 Sweden companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 68 Sweden companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 69 Sweden companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 70 Norway companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 71 Norway companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 72 Norway companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 73 Norway companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 74 Norway companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific companion diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 77 Asia Pacific companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 78 Asia Pacific companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 79 Asia Pacific companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 80 Asia Pacific companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 81 Japan companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 82 Japan companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 83 Japan companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 84 Japan companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 85 Japan companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 86 China companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 87 China companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 88 China companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 89 China companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 90 China companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 91 India companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 92 India companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 93 India companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 94 India companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 95 India companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 96 Australia companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 97 Australia companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 98 Australia companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 99 Australia companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 100 Australia companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 101 South Korea companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 102 South Korea companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 103 South Korea companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Korea companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 105 South Korea companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 106 Thailand companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 107 Thailand companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 108 Thailand companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 109 Thailand companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 110 Thailand companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 111 Latin America companion diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 112 Latin America companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 113 Latin America companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 114 Latin America companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 115 Latin America companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 116 Latin America companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 117 Brazil companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 118 Brazil companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 119 Brazil companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 120 Brazil companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 121 Brazil companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 122 Argentina companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 123 Argentina companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 124 Argentina companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 125 Argentina companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 126 Argentina companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 127 MEA companion diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 128 MEA companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 129 MEA companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 130 MEA companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 131 MEA companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 132 MEA companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 133 South Africa companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 134 South Africa companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 135 South Africa companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 136 South Africa companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 137 South Africa companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 138 Saudi Arabia companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 143 UAE companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 144 UAE companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 145 UAE companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 146 UAE companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 147 UAE companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 148 Kuwait companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
  • Table 149 Kuwait companion diagnostics market, by indication, 2018 - 2030 (USD Million)
  • Table 150 Kuwait companion diagnostics market, by technology, 2018 - 2030 (USD Million)
  • Table 151 Kuwait companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
  • Table 152 Kuwait companion diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Companion Diagnostics market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot - 1
  • Fig. 14 Segment snapshot - 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Companion Diagnostics market: Product and Services outlook key takeaways
  • Fig. 20 Companion Diagnostics market: Product and Services movement analysis
  • Fig. 21 Assays, kits, and reagents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Instruments and systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Software and services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Companion Diagnostics market: Indication outlook key takeaways
  • Fig. 25 Companion Diagnostics market: Indication movement analysis
  • Fig. 26 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Other Indications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Companion Diagnostics market: Technology outlook key takeaways
  • Fig. 32 Companion Diagnostics market: Technology movement analysis
  • Fig. 33 Polymerase Chain Reaction (PCR) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Next-generation Sequencing (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 In-situ Hybridisation (ISH) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Immunohistochemistry (IHC) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Magnetic Resonance Imaging (MRI) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Other technology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Companion Diagnostics market: Sample Type outlook key takeaways
  • Fig. 40 Companion Diagnostics market: Sample Type movement analysis
  • Fig. 41 Tissue samples market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Blood samples market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Other sample types market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Companion Diagnostics market: End-use outlook key takeaways
  • Fig. 45 Companion Diagnostics market: End-use movement analysis
  • Fig. 46 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Diagnostics Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Academic and Research Centers
  • Fig. 50 Hospitals and Physician Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Reference Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Pharmaceutical and Biotechnology Companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Other End-use market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Regional marketplace outlook, 2024 & 2030 (USD Million)
  • Fig. 56 Regional marketplace: Key takeaways
  • Fig. 57 North America companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 U.S. companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Canada companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Mexico companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Europe companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 UK companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Germany companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 France companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Spain companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Italy companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Denmark companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Sweden companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Norway companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Asia Pacific companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Japan companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 China companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 India companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Australia companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Korea companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Thailand companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Market participant categorization
  • Fig. 96 Companion Diagnostics market position analysis, 2023
  • Fig. 97 Strategic framework
目次
Product Code: GVR-4-68040-536-9

Companion Diagnostics Market Growth & Trends:

The global companion diagnostics market size is expected to reach USD 15.98 billion by 2030, registering a CAGR of 10.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. Companion diagnostics are specialized tests designed to ensure the safe and effective use of specific therapeutic products by identifying corresponding biomarkers in patients. These tests are predominantly employed in oncology, where they guide clinicians in selecting the most appropriate targeted therapies based on a patient's unique genetic profile. For instance, Foundation Medicine's FOUNDATIONONE CDx analyzes over 300 cancer-related genes, providing critical insights that inform precision cancer treatments across various solid tumors. By identifying key mutations or genetic alterations, companion diagnostics facilitate personalized treatment regimens, thereby improving clinical outcomes and reducing the risk of adverse reactions. This individualized approach to therapy not only enhances patient care but also supports the broader shift towards precision medicine, where treatment strategies are tailored to the genetic makeup of each patient.

Regulatory approvals play a pivotal role in bolstering the companion diagnostics market, particularly in oncology. In August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test, a companion diagnostic designed to identify HER2 (ERBB2) activating mutations-including single nucleotide variants and exon 20 insertions-in non-small cell lung cancer tumors. Such regulatory endorsements validate the clinical utility of these tests and promote their widespread adoption. Additionally, the use of advanced techniques such as Next-Generation Sequencing (NGS) has become integral to companion diagnostics. NGS enables clinicians to evaluate multiple genes simultaneously, thereby providing comprehensive tumor profiling. The Centers for Disease Control and Prevention (CDC) has highlighted that NGS has successfully transitioned from a research tool to a clinically approved method within the past five years, underscoring its growing importance in diagnostic applications.

Technological innovation is a critical driver of growth in the companion diagnostics market. Key industry players are continuously advancing NGS platforms, digital ELISA, and liquid biopsy techniques to improve diagnostic precision and efficiency. Strategic partnerships are further accelerating these developments; for instance, in November 2023, QIAGEN partnered with Element Biosciences to provide NGS workflows for the benchtop sequencer AVITI System, aiming to enhance discovery, reduce costs, and improve turnaround times in genomic research. Similarly, in January 2022, Illumina Inc. collaborated with SomaLogic Operating Co., Inc. to integrate the SomaScan proteomics assay into its high-throughput NGS platforms. These collaborations not only expand the technological capabilities of companion diagnostics but also foster innovation in the development of new testing solutions, ensuring that emerging diagnostic methods keep pace with evolving clinical needs.

The rising prevalence of cancer globally has significantly spurred the adoption of companion diagnostics, as genomic testing offers a detailed insight into tumor biology that is critical for selecting effective treatment protocols. According to data from the American Cancer Society Journal, approximately 1.9 million new cancer cases were reported in the U.S. in 2022, while the World Health Organization (WHO) noted that in the same year, there were 2.26 million new breast cancer cases and 2.21 million new lung cancer cases worldwide. In response to these challenges, novel tests are being developed to detect specific genetic mutations. For example, in August 2020, the U.S. FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that employs NGS technology to detect EGFR gene mutations in metastatic non-small cell lung cancer. In October 2023, QIAGEN further strengthened its market position by partnering with Myriad Genetics to develop advanced companion diagnostic solutions for oncology, thereby enhancing personalized treatment strategies and improving patient outcomes.

Companion Diagnostics Market Report Highlights:

  • Based on product and services segment, assays, kits, and reagents led the market with a 59.1% share in 2024, driven by increasing demand for personalized medicine and targeted therapies. These components are crucial in detecting specific biomarkers that help determine a patient's eligibility for precision treatments, particularly in oncology, cardiovascular diseases, and rare genetic disorders.
  • Based on indication, oncology held the dominant market share in 2024, driven by the increasing global cancer burden and the growing demand for personalized medicine. CDx plays a crucial role in identifying biomarkers that help select targeted therapies, improving treatment outcomes for cancer patients.
  • Based on technology, the Polymerase Chain Reaction (PCR) segment dominated the companion diagnostics market in 2024, holding a 27.7% share. Real-time PCR assays are widely used due to their high specificity and sensitivity, making them a preferred method for identifying cancer biomarkers
  • Based on sample type, tissue samples held the largest market share of 62.7% in 2024, driven by the widespread adoption of biomarker-based tissue testing for targeted therapies. Tissue samples are essential for identifying genetic mutations and protein expressions in solid tumors, guiding precision medicine in oncology.
  • Based on end use, the hospitals and physician laboratories segment dominated the oncology companion diagnostics market, holding a 38.6% share in 2024. Hospitals typically offer a comprehensive range of cancer diagnostic tests to address the increasing cancer burden and aging populations.
  • North America dominated the global market with a market share of 40.2% in 2024. Primarily due to advanced healthcare infrastructure, substantial healthcare expenditure, and a robust regulatory framework that expedites approvals for new diagnostic technologies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Companion Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Companion Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
    • 3.4.3. Pipeline
    • 3.4.4. Case Study

Chapter 4. Companion Diagnostics Market: Product and Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Companion Diagnostics Market: Product and Services Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Assays, Kits, and Reagents
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Instruments and Systems
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Software and Services
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Companion Diagnostics Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Companion Diagnostics Market: Indication Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Infectious Diseases
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Cardiovascular Diseases
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Neurological Disorders
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Indications
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Companion Diagnostics Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Companion Diagnostics Market: Sample Type Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Polymerase Chain Reaction (PCR)
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Next-generation Sequencing (NGS)
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. In-situ Hybridisation (ISH)
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Immunohistochemistry (IHC)
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Magnetic Resonance Imaging (MRI)
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Other Technology
    • 6.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Companion Diagnostics Market: Sample Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Companion Diagnostics Market: Sample Type Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Tissue Samples
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Blood Samples
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Sample Types
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Companion Diagnostics Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Companion Diagnostics Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 8.3. Academic and Research Centers
    • 8.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Hospitals and Physician Laboratories
    • 8.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. CROs
    • 8.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Reference Laboratories
    • 8.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Pharmaceutical and Biotechnology Companies
    • 8.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Other End-use
    • 8.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Companion Diagnostics Market: Regional Estimates & Trend Analysis

  • 9.1. Companion Diagnostics Market Share, By Region, 2024 & 2030 (USD Million)
  • 9.2. North America
    • 9.2.1. North America Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Canada Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Mexico Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. UK Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Germany Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. France Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Italy Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Spain Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Denmark Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Sweden Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Norway Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Japan Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. China
      • 9.4.3.1. China Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. India Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. Australia
      • 9.4.5.1. Australia Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. South Korea
      • 9.4.6.1. South Korea Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Thailand Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. South Africa Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. UAE Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Kuwait Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Heat Map Analysis
  • 10.4. Company Profiles
    • 10.4.1. QIAGEN
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product and Services Benchmarking
      • 10.4.1.4. Recent Developments/ Strategic Initiatives
    • 10.4.2. Agilent Technologies, Inc.
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product and Services Benchmarking
      • 10.4.2.4. Recent Developments/ Strategic Initiatives
    • 10.4.3. Abbott
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product and Services Benchmarking
      • 10.4.3.4. Recent Developments/ Strategic Initiatives
    • 10.4.4. Thermo Fisher Scientific, Inc.
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product and Services Benchmarking
      • 10.4.4.4. Recent Developments/ Strategic Initiatives
    • 10.4.5. F. Hoffmann La Roche Ltd
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product and Services Benchmarking
      • 10.4.5.4. Recent Developments/ Strategic Initiatives
    • 10.4.6. Foundation Medicine
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product and Services Benchmarking
      • 10.4.6.4. Recent Developments/ Strategic Initiatives
    • 10.4.7. Myriad Genetics
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product and Services Benchmarking
      • 10.4.7.4. Recent Developments/ Strategic Initiatives
    • 10.4.8. Illumina, Inc.
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product and Services Benchmarking
      • 10.4.8.4. Recent Developments/ Strategic Initiatives